Chinese Public Healthcare Insurance Official Defends Steep Drug Price Cuts

 
• By Dexter Jie Yan

China’s National Healthcare Security Administration (NHSA) seems determined to require pharma firms to comply with the agency’s request to cap the prices of innovative drugs, according to a senior official directly involved in annual price negotiations.

NHSA spending on novel drugs
China's NHSA expects drug makers to have a rough estimate of discounts needed for NRDL inclusion • Source: Shutterstock

More from China

More from Asia